This trial is designed to improve cardiovascular care for adult cancer survivors. The goal is to gather data to plan and develop a nation-wide network of a screening program that can help provide cost-effective and long-term monitoring.
- Cardiovascular Disease
3 Primary · 5 Secondary · Reporting Duration: 1 year
2 Treatment Groups
1 year follow-up
1 of 2
Prior to anthracycline-based therapy
1 of 2
200 Total Participants · 2 Treatment Groups
Primary Treatment: 1 year follow-up · No Placebo Group · N/A
Who is running the clinical trial?
Age 18 - 99 · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this research endeavor presently recruiting participants?
"At this time, the information hosted on clinicaltrials.gov reveals that recruitment for this trial is still taking place. The original posting was March 3rd 2022 and it has been reviewed as recently as November 15th of the same year." - Anonymous Online Contributor
What are the principal goals of this experiment?
"This clinical trial will be evaluating the diagnostic performance of NT-pro-BNP for left ventricular ejection fraction (LVEF) < 50%, over a 1 year post anthracycline therapy period. Secondary outcomes include assessing absolute change in LVEF and NT-pro BNP from baseline to one year after starting treatment, as well as determining any correlations between changes in these two variables." - Anonymous Online Contributor
How much support has this experiment gained from the public?
"Affirmative. Information hosted on clinicaltrials.gov corroborates that this medical trial, which was inaugurated on March 3rd 2022, is actively seeking participants. Around 200 individuals must be enrolled from a single research facility for the study to continue." - Anonymous Online Contributor
Are individuals under the age of 30 being accepted into this research initiative?
"The criteria for participation in this medical trial states that applicants must be 18 years or older, but cannot exceed the age of 99." - Anonymous Online Contributor
Are there any qualifications for participating in this trial?
"To qualify for this clinical trial, applicants must be between 18 and 99 years of age with a pre-existing cardiovascular condition. Additionally, they need to have been diagnosed breast cancer, lymphoma or sarcoma; plus they must either be currently undergoing or one year post completion of anthracycline therapy." - Anonymous Online Contributor